Associations of adipokines and hyperLDL-C in young adults with abdominal obesity

The aim of the study was to examine the relationships between adipokine levels and elevated low-density lipoprotein cholesterol (LDL-C) in individuals aged 25–44 years, with and without abdominal obesity (AO). Material and methods . The study included individuals aged 25–44 years, divided into groups based on the presence/absence of AO and LDL-C levels. Anthropometric parameters, lipid profile (LDL-C, HDL-C, TG, total cholesterol), carbohydrate metabolism markers, and concentrations of certain adipokines were assessed. Statistical data processing was performed using the SPSS 13.0 software package. Results . In all groups of individuals with LDL-C ≥ 3.0 mmol/L, atherogenic changes in the lipid profile, increased blood pressure and glucose levels were observed; however, the severity of concomitant metabolic disorders depended on the presence of AO. Levels of plasminogen activator inhibitor type 1 (PAI-1) (OR 1.010, 95 %, CI 1.000–1.019, p = 0.047) and C-peptide (OR 1.262, 95 %, CI 1.053–1.512, p = 0.012) demonstrated statistically significant associations with elevated LDL-C, regardless of WC. However, when including both molecules in the model, associations were obtained only for C-peptide (OR 1.416, 95 %, CI 1.079–1.858, p = 0.012) and age (OR 1.038, 95 %, CI 1.011–1.065, p = 0.006). Conclusions . Young individuals with LDL-C ≥ 3.0 mmol/L are more likely to exhibit signs of metabolic dysfunction and abnormal visceral adipose tissue activity, manifested by elevated adipocytokines. In young individuals, the risk of having hyperLDL-C is associated with increasing age and elevated C-peptide and PAI-1 levels, regardless of gender or the presence of AO.